Press Releases

Date	Title	PDF Version
Mar 05, 2019	Alexion to Present at the Cowen 39th Annual Health Care Conference
Feb 28, 2019	Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
Feb 22, 2019	FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Feb 21, 2019	Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Feb 12, 2019	Alexion Announces Creation of New Roles on Executive Leadership Team
Feb 04, 2019	Alexion Reports Fourth Quarter and Full Year 2018 Results
Feb 01, 2019	Alexion to Highlight Rare Disease Portfolio at Investor Day
Jan 31, 2019	Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis
Jan 28, 2019	Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS™ (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Jan 21, 2019	Alexion Provides Update On EU Formulation Patent For SOLIRIS® (Eculizumab)

Search